---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-074598"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:28:23.040388+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M

## Summary
- Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
- Q3 FY2025 ended Jan 31, 2025: no revenue, cash $2.6M, shareholders' equity $1.8M.
- MyoVista wavECG device clinical validation nearing completion; FDA submission expected first half calendar 2025.
- Low ejection fraction algorithm pre-validation with Rutgers; aim for FDA submission in second half 2025.
- CMS 2025 OPPS final rule includes AI-ECG reimbursement effective Jan 2025, enabling payment upon commercial launch.

## SEC filing metadata
- accession: 0000950170-25-074598
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017025074598/0000950170-25-074598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017025074598/hscs-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-074598
- JSON: https://secwatch.observer/filing/0000950170-25-074598.json
- Plain text: https://secwatch.observer/filing/0000950170-25-074598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.